Myofibrillar myopathy type 6 (MFM6) is a rare genetic muscle disorder that leads to severe muscle weakness and a drastically shortened life expectancy due to a disruption in muscle protein regulation.

Findings show that impaired autophagy leads to muscle degeneration, inflammation, and mitochondrial defects, while ...

Myofibrillar myopathy type 6 (MFM6) is a rare genetic muscle disorder that leads to severe muscle weakness and a drastically ...

Detailed price information for ME Therapeutics Holdings Inc. (METX-CN) from The Globe and Mail including charting and trades.

Researchers at the University Hospital Bonn have developed a humanized mouse model for myofibrillar myopathy type 6 (MFM6), revealing that impaired autophagy driven by a defective BAG3 protein leads ...

Dr. Marco A. M. Prado is a distinguished neuroscientist and Tier 1 Canada Research Chair in Neurochemistry of Dementia. His ...

Researchers at the University Hospital Bonn have identified a breakdown in autophagy, the cell’s recycling system, as the primary cause of myofibrillar myopathy type 6 (MFM6). Using a humanized mouse ...

Strand Therapeutics, a clinical-stage biotechnology company pioneering programmable mRNA medicines, today announced it will present preclinical data from its in vivo CAR-T program at the 2026 American ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...

Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.

The field of cancer immunotherapy and immunology is rapidly reshaping modern oncology, yet the translational gap between mechanistic discoveries and durable ...